SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
<h4>Introduction</h4>Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reductio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0263285 |
| _version_ | 1818487827928711168 |
|---|---|
| author | Judit Hodrea Adar Saeed Agnes Molnar Attila Fintha Adrienn Barczi Laszlo J Wagner Attila J Szabo Andrea Fekete Dora B Balogh |
| author_facet | Judit Hodrea Adar Saeed Agnes Molnar Attila Fintha Adrienn Barczi Laszlo J Wagner Attila J Szabo Andrea Fekete Dora B Balogh |
| author_sort | Judit Hodrea |
| collection | DOAJ |
| description | <h4>Introduction</h4>Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reduction in the relative risk of heart failure by sodium-glucose cotransporter 2 inhibitors (SGLT2i) are partly beyond their glucose lowering effects, however, the molecular mechanisms are still elusive. Here we investigated the role of SGLT2i dapagliflozin (DAPA) in the prevention of diabetes-induced cardiovascular complications.<h4>Methods</h4>Type 1 diabetes was induced with streptozotocin (65 mg/bwkg, ip.) in adult, male Wistar rats. Following the onset of diabetes rats were treated for six weeks with DAPA (1 mg/bwkg/day, po.).<h4>Results</h4>DAPA decreased blood glucose levels (D: 37±2.7 vs. D+DAPA: 18±5.6 mmol/L; p<0.05) and prevented metabolic decline. Aortic intima-media thickening was mitigated by DAPA. DAPA abolished cardiac hypertrophy, and myocardial damage. Cardiac inflammation and fibrosis were also moderated after DAPA treatment.<h4>Conclusions</h4>These data support the preventive and protective role of SGLT2i in diabetes-associated cardiovascular disease. SGLT2i may provide novel therapeutic strategy to hinder the development of cardiovascular diseases in type 1 diabetes, thereby improve the outcomes. |
| first_indexed | 2024-12-10T16:43:03Z |
| format | Article |
| id | doaj.art-591db25317ef493b996c53f5917a1e8d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T16:43:03Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-591db25317ef493b996c53f5917a1e8d2022-12-22T01:41:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172e026328510.1371/journal.pone.0263285SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.Judit HodreaAdar SaeedAgnes MolnarAttila FinthaAdrienn BarcziLaszlo J WagnerAttila J SzaboAndrea FeketeDora B Balogh<h4>Introduction</h4>Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reduction in the relative risk of heart failure by sodium-glucose cotransporter 2 inhibitors (SGLT2i) are partly beyond their glucose lowering effects, however, the molecular mechanisms are still elusive. Here we investigated the role of SGLT2i dapagliflozin (DAPA) in the prevention of diabetes-induced cardiovascular complications.<h4>Methods</h4>Type 1 diabetes was induced with streptozotocin (65 mg/bwkg, ip.) in adult, male Wistar rats. Following the onset of diabetes rats were treated for six weeks with DAPA (1 mg/bwkg/day, po.).<h4>Results</h4>DAPA decreased blood glucose levels (D: 37±2.7 vs. D+DAPA: 18±5.6 mmol/L; p<0.05) and prevented metabolic decline. Aortic intima-media thickening was mitigated by DAPA. DAPA abolished cardiac hypertrophy, and myocardial damage. Cardiac inflammation and fibrosis were also moderated after DAPA treatment.<h4>Conclusions</h4>These data support the preventive and protective role of SGLT2i in diabetes-associated cardiovascular disease. SGLT2i may provide novel therapeutic strategy to hinder the development of cardiovascular diseases in type 1 diabetes, thereby improve the outcomes.https://doi.org/10.1371/journal.pone.0263285 |
| spellingShingle | Judit Hodrea Adar Saeed Agnes Molnar Attila Fintha Adrienn Barczi Laszlo J Wagner Attila J Szabo Andrea Fekete Dora B Balogh SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS ONE |
| title | SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. |
| title_full | SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. |
| title_fullStr | SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. |
| title_full_unstemmed | SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. |
| title_short | SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. |
| title_sort | sglt2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes |
| url | https://doi.org/10.1371/journal.pone.0263285 |
| work_keys_str_mv | AT judithodrea sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT adarsaeed sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT agnesmolnar sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT attilafintha sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT adriennbarczi sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT laszlojwagner sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT attilajszabo sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT andreafekete sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes AT dorabbalogh sglt2inhibitordapagliflozinpreventsatheroscleroticandcardiaccomplicationsinexperimentaltype1diabetes |